Clinical Trials Browser

Diabetes Mellitus, Insulin-Dependent, 12 × 90 days × Clear all

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

NCT04305054 2026-04-08

KEYMAKER-U02

Phase 1/2 Active not recruiting

315 enrolled

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT07476326 2026-04-03

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

Phase 1 Not yet recruiting

120 enrolled

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasms

NCT03293784 2026-03-30

TICIMEL

Phase 1 Completed

33 enrolled

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

NCT07000149 2026-03-10

eVOLVE-RCC02

Phase 3 Active not recruiting

1,116 enrolled

Genitourinary

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Kidney Neoplasms

NCT01843374 2026-03-05

Tremelimumab

Phase 2 Active not recruiting

571 enrolled 19 charts

Other solid neoplasmThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Mesothelioma, Malignant

NCT07416058 2026-02-17

PHOENIX

Phase 2 Not yet recruiting

61 enrolled

Thoracic

Diabetes Mellitus, Insulin-Dependent, 12, Adenocarcinoma of Lung

NCT07410975 2026-02-13

Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer

Phase 2 Recruiting

54 enrolled

Thoracic

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Non-Small-Cell Lung

NCT05139706 2026-02-03

MIRAE

Recruiting

1,000 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Autoimmune Diseases, Immune System Diseases, Inflammation, Neoplasms

NCT07354971 2026-01-21

IMMUNO-FIT Observational Study

Not yet recruiting

67 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms, Drug-Related Side Effects and Adverse Reactions

Clinical Trials

LuCa-MERIT-1

KEYMAKER-U02

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

TICIMEL

eVOLVE-RCC02

Tremelimumab

PHOENIX

Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer

MIRAE

IMMUNO-FIT Observational Study